Long-Term Safety Study of Afimkibart for Rheumatoid Arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This is a follow-up study for people who already completed a previous trial testing afimkibart (an experimental drug) for rheumatoid arthritis. It checks whether the drug continues to work safely and effectively over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the treatment period in the original afimkibart study
- Your joint swelling and pain (measured by swollen and tender joint counts) improved from the start of the original study
- You attended the final follow-up visit in the original study
- You are willing to use effective birth control during the study
- You have not permanently stopped the study drug or withdrawn from the original study
- You do not have any new, uncontrolled medical conditions that would make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.